Apogee Therapeutics (APGE) Share-based Compensation (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Share-based Compensation data on file, last reported at $256000.0 in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 97.7% year-over-year to $256000.0 in Q1 2026; TTM through Mar 2026 was $23.5 million, a 22.45% decrease from a year earlier, with the FY2025 full-year figure at $110.1 million, down 18.14% from the prior year.
• Share-based Compensation for Q1 2026 stood at $256000.0, down from $11.9 million in the prior quarter.
• Over the last five years, Share-based Compensation for APGE reached as high as $180.5 million in Q4 2023 and fell as low as $256000.0 in Q1 2026.
• Historically, Share-based Compensation has averaged $20.2 million across 4 years, with a median of $5.8 million in 2024.
• Across the five-year window, Share-based Compensation jumped 411.95% in 2024 and tumbled 97.7% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $180.5 million in 2023, then tumbled by 95.78% to $7.6 million in 2024, then surged by 56.09% to $11.9 million in 2025, then slumped by 97.84% to $256000.0 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $256000.0 in Q1 2026, $11.9 million in Q3 2025, and $11.3 million in Q2 2025.